Physician profile
Joe T Sharp
NPI 1891781340
$1,680.77
in general payments reported to CMS, 2019-2025
11 companies · $432 in 2025
The $432 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $60.87 · 2021: $47.00 · 2022: $421 · 2023: $302 · 2024: $291 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $800 · Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $800.00 |
| Food and Beverage | $225.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $1,155.00 | 2022-2025 | |
| Pfizer INC. | $131.13 | 2019-2025 | |
| Abbott Laboratories | $84.93 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $75.81 | 2019-2021 | |
| Lilly USA, LLC | $68.10 | 2020-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $50.66 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.25 | 2022-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $27.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.24 | 2020 | |
| Glaxosmithkline, LLC. | $13.65 | 2022 | |
| Gilead Sciences, INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.